SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed ($WOLF) is trending due to its emergence from Chapter 11 bankruptcy, which involved restructuring and share cancellation, leading to significant price volatility. The community is actively debating the impact of the restructuring on existing shareholders and the potential for a short squeeze given the reduced float. Discussions also involve the new board appointments and the company's prospects in the silicon carbide market.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN.X is trending as the community rallies around its association with cannabis culture and related themes of freedom and growth. The coin's connection to the $UPDOG.X meme coin is also a popular talking point. Some users are excited about potential future catalysts, such as possible changes in cannabis legislation.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending on the Solana blockchain with community members frequently asking 'What's UpDog?' and celebrating new holders. Community members highlight the project's longevity and locked liquidity, viewing it as a resilient meme coin within the broader crypto space.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after a massive selloff sparked by mixed clinical trial results for its lead drug, with community members debating whether the decline was an overreaction. Despite one trial narrowly missing statistical significance, some believe the drug shows promise and the company's cash position makes it a compelling bounce-back play. The discussion includes speculation about a potential acquisition and the possibility of a short squeeze.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is trending due to community interest in its potential role in the Solana ecosystem, particularly its association with $UPDOG.X and $BROKE.X, two tokens listed on its exchange. Community members are actively discussing strategies for trading these tokens, highlighting Jupiter's position as a platform for Solana-based assets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as community members discuss the potential impact of BRIUMVI's data and a newly announced share repurchase program. Bullish sentiment is fueled by the company's commitment to shareholder value and speculation around future growth, while some investors are analyzing technical indicators for potential entry points. Discussions also include speculation about a potential buyout and comparisons to competitors in the biotech sector.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a short report raising concerns about inflated ARR, declining revenue, and related-party transactions, which the company vehemently denies, asserting its strong fundamentals and strategic partnerships with Microsoft and Google; the community is highly divided, with bullish investors citing the recent $200M capital raise and strong potential for AI-driven e-commerce solutions, while bears highlight unaudited financials and question the validity of customer relationships, with all eyes on the upcoming earnings report.

Applied DNA Sciences, Inc. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Applied Dna Sciences Inc

Applied DNA Sciences is trending due to a recently announced private placement of up to $58 million to initiate a BNB-focused digital asset treasury, a pivot that has investors and the Stocktwits community actively discussing the company's new direction and potential. Some are optimistic about the biotech-meets-crypto strategy, while others express concerns about dilution and long-term viability, also mentioning Anthony Scaramucci's advisory role.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as community members discuss recent price drops, potential support levels, and a Morgan Stanley downgrade. Some traders are concerned about overnight dumps and the stock's recent performance, while others see it as a buying opportunity, citing the company's fundamentals and potential for an oral weight loss pill. Discussions also include comparisons to competitors and speculation about future M&A activity in the weight loss drug market.

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Upstream Bio Inc.

Upstream Bio ($UPB) is trending due to positive Phase 2 trial data for verekitug, a potential treatment for severe asthma and chronic rhinosinusitis. The community is focused on the drug's mechanism and potential to disrupt the biologic treatment landscape, especially compared to existing TSLP-targeting therapies. Some are also watching key price levels, looking for breakouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delta Air Lines (DAL) CEO Ed Bastian stated on Monday that most U.S. airlines are expected to incur losses this year, as spending patterns diverge across income groups.According to a Bloomberg News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-29/delta-s-bastian-sees-most-us-airlines-losing-money-in-2025?embedded-checkout=true">report</a>, Bastian said at an event, while the upper end of the economy is spending money on travel and other experiences, “you have the lower end of the consumer spectrum, it’s tough.”During his chat with Raphael Bostic, the president of the Federal Reserve Bank of Atlanta, Bastian noted that Delta and rival United Airlines Holdings will make the majority of the profit in the industry, banking on expensive premium seats and a comeback in business travel.Retail sentiment on Stocktwits about low-cost carrier <a href="https://stocktwits.com/symbol/ULCC">Frontier Group</a> (ULCC) was in the ‘neutral’ territory at the time of writing, while traders were ‘bullish’ about <a href="https://stocktwits.com/symbol/ALGT">Allegiant Group</a> (ALGT), as well as <a href="https://stocktwits.com/symbol/DAL">Delta</a> and <a href="https://stocktwits.com/symbol/UAL">United Airlines</a> stocks.<figure class="image"><img style="aspect-ratio:797/103;" src="https://news.stocktwits-cdn.com/ULCC_Sept_29_JPG_685818c03c.webp" alt="ULCC-Sept 29.JPG" width="797" height="103"><figcaption>ULCC’s Sentiment Meter and Message Volume as of 10:46 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>Delta had earlier earmarked “solid” corporate bookings and high-yield leisure travel as key earnings drivers during the fall season.In April, Delta, along with many other U.S. airlines, including American Airlines (AAL) and JetBlue Airways (JBLU), withdrew its annual expectations for the year, as the tariff war had resulted in economic uncertainty and a decline in consumer confidence during the first half of the year.The dip in demand toward the back half of the cabin, combined with rising costs, has severely eroded margins at low-cost carriers. Earlier this month, Spirit Airlines, which filed for bankruptcy for the second time in less than a year, revealed plans for further job cuts and a reduction in flight schedule in November to cut costs.United's stock is up 1.4% this year, while Delta's is down 4.3%. In comparison, Frontier stock has fallen 32.8% and Allegiant stock is down nearly 34%.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-firefly-aerospace-stock-tumble-over-12-after-hours-today/chDwteUR3JF">Why Did Firefly Aerospace Stock Tumble Over 12% After-Hours Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Delta Airlines Airbus A320 arrives at Los Angeles International Airport from Dallas on March 28, 2025 in Los Angeles, California. (Photo by Kevin Carter/Getty Images)

Delta Air Lines CEO Expects Most US Carriers To Bleed In 2025: Report

Ed Bastian noted that the carrier and its rival, United Airlines Holdings, will generate the majority of the industry's profit.

Equity

Airline Stock Roundup: DAL's Improved Q3 Revenue View, ALGT in Focus

DAL lifts Q3 revenue view on strong travel demand, while ALGT posts double-digit August traffic growth despite load factor dip.

Copa Holdings' August 2025 Traffic Improves Year Over Year

CPA posts strong August traffic with RPM up 9.8% and load factor rising to 88.3% as demand outpaces capacity growth.

Allegiant August 2025 Traffic Numbers Improve Year Over Year

ALGT's August traffic rose year over year, but traffic growth lagged capacity expansion leading to a dip in load factor.

Allegiant to Launch New Nonstop Flights for Boosting Connectivity

The latest move is expected to boost ALGT's competitive position in the airline industry.

Allegiant Travel (ALGT) Up 32% Since Last Earnings Report: Can It Continue?

Allegiant Travel (ALGT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Airline Stock Roundup: ALGT's Impressive July Traffic, DAL, LUV in Focus

ALGT posts double-digit July traffic growth, while DAL, LUV, ALK and ULCC unveil major route expansions and strategic moves.

Allegiant July 2025 Traffic Numbers Improve Year Over Year

ALGT's July traffic rose year over year, but capacity outpaced demand, leading to a dip in load factor despite strong growth.

Here's Why You Should Give Allegiant Stock a Miss Now

ALGT faces steep earnings cuts, a 20% share drop and soaring expenses, signaling mounting financial and operational strain.

Allegiant Q2 Earnings Surpass Estimates, Decline Year Over Year

ALGT's second-quarter 2025 earnings decline year over year while revenues improve.

Allegiant Travel Co. engages in the provision of leisure travel services. It operates through the Airline and Sunseeker Resort segments. The Airline segment involves the scheduled service air transportation, ancillary air-related and third-party products and services, fixed fee contract air transportation, and other airline-related revenue. The Sunseeker Resort segment includes hotel rooms and suites for occupancy, group meeting facilities, food and beverage options, the Aileron Golf Course, and other resort amenities. The company was founded in 1997 and is headquartered in Las Vegas, NV.

Allegiant Travel

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$1.91	--	--	N/A
Q2 '25	$0.77	$1.23	59.32%	BEAT
Q1 '25	$1.54	$1.81	17.21%	BEAT
Q4 '24	$2.07	$2.10	1.25%	BEAT
Q3 '24	-$1.87	-$2.02	-7.96%	MISSED

ALGT
Allegiant Travel

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ALGT News

ALGT Allegiant Travel